Shanghai And Hong Kong,, April 24, 2025 / Prnewswire / – Antengene Corporation Limited (“Antenanene“, Sehk: 6996.hk), a world innovative global biopharmaceutical business dedicated to the discovery, development and marketing of first -rate drugs and / or the best drugs for hematological tumors and solid tumors, announced today that He will publish the latest clinical data of the inhibitor of small CD73 ATG-037 molecules and the inhibitor of small MTORC1 / 2 ATG-008 molecule in poster presentations of the annual meeting of the American Society of Clinical ONCOLOGY (ASCO) of the American Society of Clinical Oncology (ASCO), which takes place from from since May 30th has June 3RD In Chicago, the,, The United States.
Previously, Antengene has concluded global clinical collaboration with MSD (Merck & Co., Inc., Rahway, njUSA) on the IB IB phase trial ATG-037 assessment in combination with MSD anti-PD-1 therapy, Keytruda® (Pembrolizumab), in patients with strong anti-PD-1-resistant tumors, with encouraging preliminary results in melanoma and lung cancer non-small cells (NSCLC). Currently, the optimization and expansion part of the study dose China And Australia.
Details of the poster presentations:
ATG-037 (inhibitor of small CD73 molecule)
Title: A first I / IB study of the first phase of humanity in ATG-037 in monotherapy and therapy combined with pembrolizumab in patients with advanced solid tumors: endurance-01
Abstract: 3123
Session: Development therapy – targeted molecular agents and tumor biology
Date: June 2, 2025
Time: 1:30 p.m. – 4:30 p.m. (central time)
2h30 – 5:30 am,, June 3, 2025 (Beijing time)
ATG-008 (MTORC1 / 2 Small molecule inhibitor)
Title: A TORC1 / 2 onataSetITIB inhibitor combined with TORIPALIMAB in patients with advanced cervical cancer with anterior anti-PD- (L) treatment 1 (L) 1
Abstract: 5540
Session: Gynecological cancer
Date: June 1, 2025
Time: 9:00 a.m. – 12:00 p.m. (central time)
10 p.m.,, June 1, 2025 – 1 hour morning,, June 2, 2025 (Beijing time)
Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Inc., Rahway, njUNITED STATES.
About antengene
Antengene Corporation Limited (“Antengene”. “Treat patients beyond borders”.
Antengene has built a pipeline of 9 assets in oncology at various stages ranging from clinic to advertising, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 Approval of Investigation of New Medicines (IND) in the United States and Asiaand submitted new medication requests (NDAS) in 11 Asia-Pacific markets, with the NDA for XPOVIO® (Selinexor) already approved on the continent of ChinaTaiwan China, Hong Kong ChinaMacao China, South Korea,, Singapore,, Malaysia,, Thailand,, Indonesia And Australia.
Prospective declarations
Prospective declarations made in this article only concern events or information on the date on which declarations are made in this article. Unless the law required, we have no obligation to update or publicly revise all prospective declarations, whether following new information, future or otherwise, after the date on which declarations are made or to reflect the occurrence of unforeseen events. You must read this article completely and because of the understanding that our real results or performance can be materially different from what we expect. In this article, declarations or references to our intentions or those of our administrators or our company are made on the date of this article. All of these intentions could modify in the light of future development. For a more in -depth discussion of these factors and others which could ensure that future results differ considerably from any prospective declaration, please consult the other risks and uncertainties described in the annual report of the company for the finished financial year December 31, 2024And the documents subsequently submitted to the Hong Kong Stock Exchange.
For more information, please contact:
Investor contacts:
Donald Lung
E-mail: Donald.lung@anannene.com
Mobile: +86 18420672158
Public relations contacts:
Peter Qian
E-mail: Peter.qian@anannene.com
Mobile: +86 13062747000
Show original content to download the multimedia:https://www.prnewswire.com/apac/news-releases/anannene-to–present-latest-results-from-clinical-studes-at-asco-2025-302436709.html
Source Antengene Corporation Limited
